-
Subject Areas on Research
-
A kallikrein-targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release.
-
Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621.
-
African-American men with low-risk prostate cancer treated with radical prostatectomy in an equal-access health care system: implications for active surveillance.
-
American Society of Clinical Oncology 2013 top five list in oncology.
-
Aprotinin improves functional outcome but not cerebral infarct size in an experimental model of stroke during cardiopulmonary bypass.
-
Associations Between Prostate Volume and Oncologic Outcomes in Men Undergoing Focal Cryoablation of the Prostate.
-
Associations among statins, preventive care, and prostate cancer mortality.
-
Characterization of inactive renin from human kidney and plasma. Evidence of a renal source of circulating inactive renin.
-
Characterization of prorenin activation using a synthetic peptide substrate.
-
Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide.
-
Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.
-
Dietary inflammatory index (DII) and risk of prostate cancer in a case-control study among Black and White US Veteran men.
-
Disseminated intravascular coagulation: a reappraisal.
-
Do Hispanic Men Have Worse Outcomes After Radical Prostatectomy? Results From SEARCH.
-
Emerging applications of aptamers for anticoagulation and hemostasis.
-
Evaluation of a novel kallikrein inhibitor on hemostatic activation in vitro.
-
Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation.
-
Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.
-
FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist.
-
Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer.
-
Fasting times in serum PSA assay.
-
Hierarchical Bayesian mixture modelling for antigen-specific T-cell subtyping in combinatorially encoded flow cytometry studies.
-
Hormone naïve prostate cancer: predicting and maximizing response intervals.
-
Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro.
-
Immune hemolytic transfusion reactions in monkeys: activation of the kallikrein system.
-
Impact of Low Carbohydrate Diet on Self-Report Fatigue and Weakness in Prostate Cancer Patients.
-
Kallikrein-related mRNAs of the rat submaxillary gland: nucleotide sequences of four distinct types including tonin.
-
Modulation of the BP response to diet by genes in the renin-angiotensin system and the adrenergic nervous system.
-
Null association between vitamin D and PSA levels among black men in a vitamin D supplementation trial.
-
Obesity, prostate-specific antigen nadir, and biochemical recurrence after radical prostatectomy: biology or technique? Results from the SEARCH database.
-
Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report.
-
Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer.
-
Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.
-
Predicting Time From Metastasis to Overall Survival in Castration-Resistant Prostate Cancer: Results From SEARCH.
-
Prevalence and correlates of non-tissue prostate cancer diagnosis in the United States.
-
Progesterone stimulates mitochondrial activity with subsequent inhibition of apoptosis in MCF-10A benign breast epithelial cells.
-
Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients.
-
Prostate Cancer Detection Rate of Freehand versus 3-Dimensional Template Mapping Biopsy Using a Magnetic Resonance Imaging-Ultrasound Fusion Device in Biopsy Naïve Men.
-
Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms.
-
Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay.
-
Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer.
-
Prostate-specific antigen velocity: new methods, same results, still no evidence of clinical utility.
-
Psychosocial trajectories of men monitoring prostate-specific antigen levels following surgery for prostate cancer.
-
Radical prostatectomy versus radiation therapy: can pretreatment nomograms be used to select the appropriate prostate cancer treatment?
-
Rat pancreatic kallikrein mRNA: nucleotide sequence and amino acid sequence of the encoded preproenzyme.
-
Rising PSA Level in an Anxious Postprostatectomy Patient.
-
Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial.
-
Surveillance after prostate focal therapy.
-
Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry.
-
Synergistic and tunable human gene activation by combinations of synthetic transcription factors.
-
TET2 binds the androgen receptor and loss is associated with prostate cancer.
-
The GNA13-RhoA signaling axis suppresses expression of tumor protective Kallikreins.
-
The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data.
-
The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema.
-
Timing of Prostate-specific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical Recurrence.
-
Tissue-specific expression of kallikrein-related genes in the rat.
-
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
-
Urinary kallikrein in dogs with constriction of one renal artery.
-
Keywords of People